In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsDijkstra, J A
van der Laan, T
Akkerman, O W
Bolhuis, M S
de Lange, W C M
Kosterink, J G W
van der Werf, T S
Alffenaar, J W C
van Soolingen, D
MetadataShow full item record
TitleIn vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
Published inAntimicrob Agents Chemother 2018; 62(3):e01724-17
PubliekssamenvattingAmikacin, kanamycin and capreomycin are listed among the most important 2nd line drugs for multidrug resistant tuberculosis. Although amikacin and kanamycin are administered in the same dose and show the same pharmacokinetics, they have different WHO breakpoints suggesting that the two drugs have a different minimal inhibitory concentrations (MIC). The aim of this paper was to investigate possible differences in MIC between the aminoglycosides and capreomycin.Using the direct concentration method, a concentration range of amikacin, kanamycin and capreomycin (0.25, 0.50, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 and 64.0 mg/L) was tested against 57 clinical Mycobacterium tuberculosis strains. The 7H10 agar plates were examined for mycobacterial growth after 14 days.At 2 mg/L, 48 strains (84%) were inhibited by amikacin and only five strains (9%) were inhibited by kanamycin (p < 0.05, Wilcoxon Signed Rank Test). The median MICs of amikacin, kanamycin and capreomycin were 2, 4 and 8 mg/L, respectively. No difference was observed between multidrug resistant and fully susceptible strains in the MIC-distribution of amikacin, kanamycin and capreomycin.The results indicate that amikacin is more active against M. tuberculosis than kanamycin and capreomycin in the absolute concentration method. The impact of this difference on clinical outcome in daily practice requires a prospective study including pharmacokinetic and pharmacodynamics evaluations.
- High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.
- Authors: Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L
- Issue date: 2009 Dec
- Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.
- Authors: Kambli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C
- Issue date: 2016 Mar
- Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
- Authors: Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P
- Issue date: 2011 Jun
- Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.
- Authors: Zhang Z, Liu M, Wang Y, Pang Y, Kam KM, Zhao Y
- Issue date: 2014 Nov
- Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.
- Authors: Brossier F, Pham A, Bernard C, Aubry A, Jarlier V, Veziris N, Sougakoff W, CNR-MyRMA.
- Issue date: 2017 Feb